Bone turnover 18 months after a single intravenous dose of zoledronic acid

International Journal of Clinical Practice

Volumn 61, Issue 6, 2007, Pages 1058-1062

  Borba, V Z C ^a,e   Paz Filho, G ^a   Kulak, C A M ^a   Seibel, M J ^b,c   Bilezikian, J P ^d  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b ANZAC RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Columbia University ^*  (United States)

^e NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HIP; HUMAN; LONGITUDINAL STUDY; LUMBAR SPINE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TERTIARY HEALTH CARE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 34248399498     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01392.x     Document Type: Article

References (17)

1. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002 359 : 2018 26.
2. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005 27 : 361 76.
3. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002 346 : 653 61.
4. Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 2003 15 : 458 63.
5. Black DM, Boonen S, Cauley J et al. Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON Pivotal Fracture Trial. J Bone Miner Res 2006 21 : S16.
6. Lawson MA, Triffitt JT, Ebetino FH et al. Potential bone mineral binding differences among bisphosphonates can be demonstrated by the use of hydroxyapatite column chromatography. J Bone Miner Res 2005 20 : S396.
7. Russell RGG. Determinants of structure-function relationship among biphosphonates. Bone 2007 40 : S21 5.
8. Widler L, Jaeggi KA, Glatt M et al. Highly potent geminal bisphosphonates: from pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002 45 : 3721 38
9. Bonde M, Garnero P, Fledelius C et al. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997 12 : 1028 34.
10. Peretz A, Siderova V, Body JJ et al., Interdisciplinary Group for the Study of Bone Diseases and Calcium metabolism (GIPOB). Response to alendronate in osteoporotic women previously treated with pamidronate. Maturitas 2003 44 : 111 5.
11. Orr-Walker B, Wattie DJ, Evans MC, Reid IR. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. Clin Endocrinol (Oxf) 1997 46 : 87 92.
12. Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 1995 80 : 3465 8.
13. Ravn P, Weiss SR, Rodriguez-Portales JA et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000 85 : 1492 7.
14. Odvina CV, Zerwekh JE, Sudhaker RD et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005 90 : 1294 301.
15. Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003 61 : 1115 7.
16. Shane E, Goldring S, Christakos S et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006 21 : 1503 5.
17. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl Med 2006 355 : 2278 81.